Literature DB >> 30642553

Feasibility of lung cancer RNA acquisition from a single transbronchial or transthoracic needle pass (FASTT trial).

Travis Dotson1, Christina Bellinger1, Jing Su2, Kris Hansen3, Graham E Parks4, James O Cappellari4, Lou Craddock5, Hollins Clark6, Clifford Howard6, W Jeffrey Petty3, Bharat Prakash1, Kounosuke Watabe5, Michael Chan7, Jonathan Hovda1, Lance D Miller5, Jimmy Ruiz8.   

Abstract

INTRODUCTION: RNA isolation from tumor tissue is used for biomarker analyses and validation. Limited diagnostic material from small volume biopsies combined with an increasing demand for standard histologic, molecular characterization, and next generation sequencing applications often leads to limited material for research. We sought to evaluate small volume sampling of lung cancer tissue collected from a single needle pass during a diagnostic procedure and determine if it can provide RNA of acceptable quantity and quality.
METHODS: We enrolled 140 patients with probable primary bronchogenic carcinoma and collected RNA from a dedicated FNA aspiration. Total RNA (ηg), RNA integrity number (RIN), and %Mass in base pairs were evaluated from each patient sample. A customized nanoString nCounter® 95-gene panel was used to profile the expression patterns of feature NSCLC genes. We compared gene expression patterns that distinguish lung adenocarcinoma (LUAD) and squamous cell carcinoma (LUSC) in our cohort with a corresponding Cancer Genome Atlas (TCGA) NSCLC datasets.
RESULTS: Of the 149 patients consented. RNA-extraction was performed in 101 eligible patients. A satisfactory total RNA mass and RIN was quantified for all samples with a similar distribution among cellular subtypes. Mean %-Mass over 300 base pairs was noted for all specimens and 96% of samples met criteria to perform genetic evaluation with our commercialized gene expression assay. The FNA-derived transcriptomic results showed excellent consistency with the TCGA counterparts, and the differential expression pattern of LUAD vs LUSC subtypes were highly similar. DISCUSSION: In this study, RNA retrieval from a single-pass FNA regardless of procedural approach showed equivalence and suitability for gene expression assessments. RNA extraction from small volume samples has the potential to provide valuable material for genetic profiling. Published by Elsevier B.V.

Entities:  

Keywords:  Fine needle aspiration biopsy; Gene-expression; Non-small cell lung cancer; Ribonucleic acid

Mesh:

Substances:

Year:  2018        PMID: 30642553      PMCID: PMC6386467          DOI: 10.1016/j.lungcan.2018.11.023

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  16 in total

1.  Concordance analysis: part 16 of a series on evaluation of scientific publications.

Authors:  Robert Kwiecien; Annette Kopp-Schneider; Maria Blettner
Journal:  Dtsch Arztebl Int       Date:  2011-07-29       Impact factor: 5.594

2.  Simultaneous Isolation of Total RNA, DNA, and Protein Using Samples Obtained by EBUS-TBNA.

Authors:  Takahiro Nakajima; Takashi Anayama; Terumoto Koike; Thomas Waddell; Shaf Keshavjee; Hideki Kimura; Ichiro Yoshino; Kazuhiro Yasufuku
Journal:  J Bronchology Interv Pulmonol       Date:  2011-10

3.  Molecular profiling of thin-prep FNA samples in assisting clinical management of non-small-cell lung cancer.

Authors:  Daniela Petriella; Domenico Galetta; Vincenza Rubini; Eufemia Savino; Angelo Paradiso; Giovanni Simone; Stefania Tommasi
Journal:  Mol Biotechnol       Date:  2013-07       Impact factor: 2.695

4.  Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology.

Authors:  William J Gradishar; Benjamin O Anderson; Ron Balassanian; Sarah L Blair; Harold J Burstein; Amy Cyr; Anthony D Elias; William B Farrar; Andres Forero; Sharon H Giordano; Matthew P Goetz; Lori J Goldstein; Steven J Isakoff; Janice Lyons; P Kelly Marcom; Ingrid A Mayer; Beryl McCormick; Meena S Moran; Ruth M O'Regan; Sameer A Patel; Lori J Pierce; Elizabeth C Reed; Kilian E Salerno; Lee S Schwartzberg; Amy Sitapati; Karen Lisa Smith; Mary Lou Smith; Hatem Soliman; George Somlo; Melinda L Telli; John H Ward; Rashmi Kumar; Dorothy A Shead
Journal:  J Natl Compr Canc Netw       Date:  2018-03       Impact factor: 11.908

5.  Morphologic Accuracy in Differentiating Primary Lung Adenocarcinoma From Squamous Cell Carcinoma in Cytology Specimens.

Authors:  Maureen F Zakowski; Natasha Rekhtman; Manon Auger; Christine N Booth; Barbara Crothers; Mohiddean Ghofrani; Walid Khalbuss; Rodolfo Laucirica; Ann T Moriarty; Z Laura Tabatabai; Güliz A Barkan
Journal:  Arch Pathol Lab Med       Date:  2016-08-23       Impact factor: 5.534

Review 6.  The NCI Genomic Data Commons as an engine for precision medicine.

Authors:  Mark A Jensen; Vincent Ferretti; Robert L Grossman; Louis M Staudt
Journal:  Blood       Date:  2017-06-09       Impact factor: 22.113

7.  Interobserver agreement in determining non-small cell lung cancer subtype in specimens acquired by EBUS-TBNA.

Authors:  Daniel P Steinfort; Prudence A Russell; Alpha Tsui; Gordon White; Gavin Wright; Louis B Irving
Journal:  Eur Respir J       Date:  2012-02-09       Impact factor: 16.671

Review 8.  Evaluation of individuals with pulmonary nodules: when is it lung cancer? Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.

Authors:  Michael K Gould; Jessica Donington; William R Lynch; Peter J Mazzone; David E Midthun; David P Naidich; Renda Soylemez Wiener
Journal:  Chest       Date:  2013-05       Impact factor: 9.410

Review 9.  Role of the pulmonologist in ordering post-procedure molecular markers in non-small-cell lung cancer: implications for personalized medicine.

Authors:  Septimiu Murgu; Henri Colt
Journal:  Clin Lung Cancer       Date:  2013-11       Impact factor: 4.785

10.  EBUS-TBNA provides highest RNA yield for multiple biomarker testing from routinely obtained small biopsies in non-small cell lung cancer patients - a comparative study of three different minimal invasive sampling methods.

Authors:  Gerald Schmid-Bindert; Yongsheng Wang; Hongbin Jiang; Hui Sun; Thomas Henzler; Hao Wang; Lothar R Pilz; Shengxiang Ren; Caicun Zhou
Journal:  PLoS One       Date:  2013-10-29       Impact factor: 3.240

View more
  1 in total

1.  Comprehensive and Computable Molecular Diagnostic Panel (C2Dx) From Small Volume Specimens for Precision Oncology: Molecular Subtyping of Non-Small Cell Lung Cancer From Fine Needle Aspirates.

Authors:  Jing Su; Lynn S Huang; Ryan Barnard; Graham Parks; James Cappellari; Christina Bellinger; Travis Dotson; Lou Craddock; Bharat Prakash; Jonathan Hovda; Hollins Clark; William Jeffrey Petty; Boris Pasche; Michael D Chan; Lance D Miller; Jimmy Ruiz
Journal:  Front Oncol       Date:  2021-04-16       Impact factor: 6.244

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.